Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 5.9%. This performance was discouraging since the S&P 500 held steady.
A cautious approach is imperative when dabbling in these businesses as regulation is another unpredictable element that can affect their earnings potential. On that note, here are three healthcare stocks that may face trouble.
AbbVie (ABBV)
Market Cap: $369.3 billion
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
Why Do We Think Twice About ABBV?
- Constant currency growth was below our standards over the past two years, suggesting it might need to invest in product improvements to get back on track
- Inability to adjust its cost structure while its revenue declined over the last two years led to a 10.6 percentage point drop in the company’s adjusted operating margin
- Performance over the past five years shows its incremental sales were less profitable, as its 2.5% annual earnings per share growth trailed its revenue gains
AbbVie’s stock price of $209.00 implies a valuation ratio of 17x forward price-to-earnings. If you’re considering ABBV for your portfolio, see our FREE research report to learn more.
Bausch + Lomb (BLCO)
Market Cap: $5.61 billion
With a nearly 170-year history dedicated to vision care and eye health innovation, Bausch + Lomb (NYSE: BLCO) develops and manufactures a comprehensive range of eye health products including contact lenses, pharmaceuticals, surgical devices, and consumer eye care solutions.
Why Does BLCO Fall Short?
- Sales trends were unexciting over the last five years as its 5% annual growth was below the typical healthcare company
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 23.5% annually while its revenue grew
- Short cash runway increases the probability of a capital raise that dilutes existing shareholders
At $15.93 per share, Bausch + Lomb trades at 20.8x forward price-to-earnings. To fully understand why you should be careful with BLCO, check out our full research report (it’s free).
iRhythm (IRTC)
Market Cap: $3.33 billion
Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ: IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders.
Why Does IRTC Worry Us?
- Earnings per share fell by 7.5% annually over the last five years while its revenue grew, partly because it diluted shareholders
- Negative free cash flow raises questions about the return timeline for its investments
- Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders
iRhythm is trading at $106.42 per share, or 63.9x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including IRTC in your portfolio.
Stocks We Like More
The Trump trade may have passed, but rates are still dropping and inflation is still cooling. Opportunities are ripe for those ready to act - and we’re here to help you pick them.
Get started by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.
Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free.
